BofA Downgrades Moderna To Underperform, Sees Shares Priced For 'Best-Case'
February 01, 2021 at 10:20 AM EST
As previously reported, BofA analyst Geoff Meacham downgraded Moderna to Underperform from Neutral with an unchanged price target of $150.